Company Overview
By using the body’s immune system, Anixa Biosciences is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.
Recent News
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Stock Overview
Symbol
ANIX
Exchange
Nasdaq
Market Cap
97.99m
Last Price
$3.045
52-Week Range
$2.145 - $5.13
11/20/2024 09:00 PM EST
Investor Relations
Mike Catelani
President, COO & CFO
T: 408-708-9808